Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), Novo Nordisk A/S ...

Helgi Kormaksson Joins CTS Executive Team SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / CTS is excited to announce that Helgi Kormaksson has joined the company as Chief Design Officer. Helgi ...

Six lung cancer patients and one care partner were selected as the inaugural LiveLung ASCO Scholars and traveled here for the American Society of Clinical Oncology annual meeting at McCormick Place ...

Nanalysis Scientific Corp. (the "Company" or "Nanalysis") , is pleased to announce an offering of 12% unsecured promissory notes (the "Notes") for aggregate gross proceeds of $2,000,000 (the "Offering ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...